Alpha 2.0
Login Register
» Articles » PMID: 21093053

Sorafenib for Refractory FMS-like Tyrosine Kinase Receptor-3 (FLT3/ITD+) Acute Myeloid Leukemia After Allogenic Stem Cell Transplantation

Overview
Journal Leuk Res
Date 2010 Nov 25
PMID 21093053
Citations 10
Authors
Federica Sora
Patrizia Chiusolo
Elisabetta Metafuni
Silvia Bellesi
Sabrina Giammarco
Luca Laurenti
Giuseppe Ausoni
Gina Zini
Alina J Bayer
Balducci Mario
Giuseppe Leone
Simona Sica
Affiliations
Soon will be listed here.
Citing Articles

Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.

Tamellini E, Sorio M, Andreini A, Tecchio C, Nadali G, Bernardelli A Blood Cell Ther. 2024; 7(3):75-78.

PMID: 39263622 PMC: 11384128. DOI: 10.31547/bct-2024-005.

Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patients.

Mima F, Fuji S, Shibata K, Kida S, Tsutsumi K, Tada Y Blood Cell Ther. 2023; 6(3):77-79.

PMID: 38146352 PMC: 10749211. DOI: 10.31547/bct-2023-003.

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.

Biavasco F, Zeiser R Int J Hematol. 2022; 116(3):341-350.

PMID: 35460465 PMC: 9392688. DOI: 10.1007/s12185-022-03352-6.

A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.

Pratz K, Rudek M, Smith B, Karp J, Gojo I, DeZern A Biol Blood Marrow Transplant. 2019; 26(2):300-306.

PMID: 31550496 PMC: 7001148. DOI: 10.1016/j.bbmt.2019.09.023.

How I treat FLT3-mutated AML.

Pratz K, Levis M Blood. 2016; 129(5):565-571.

PMID: 27872057 PMC: 5290983. DOI: 10.1182/blood-2016-09-693648.